Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2020;383:30 de diciembre. [Ref.ID 103836]

Weiland N, LaFraniere S, Baker M, Thomas K. 2 Alaska health workers got emergency treatment after receiving Pfizer’s vaccine. N Y Times (Print) 2020:16 de diciembre. [Ref.ID 103820]

Tena B. UK recomienda que las personas alérgicas no se vacunen al registrar dos casos de reacciones. El Confidencial 2020:4. [Ref.ID 103810]

Castells M, Khan DA, Phillips EJ. Penicillin allergy. N Engl J Med 2019;381:12 de diciembre. [Ref.ID 103229]

Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory disease — New prime suspects. N Engl J Med 2016;374:484-8. [Ref.ID 99993]

Thong BYH, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011;71:684-700. [Ref.ID 90601]

Arden-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71:672-83. [Ref.ID 90600]

Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol 2011;71:659-71. [Ref.ID 90599]

Nel L, Eren E. Peri-operative anaphylaxis. Br J Clin Pharmacol 2011;71:647-58. [Ref.ID 90598]

Frew A. General principles of investigating and managing drug allergy. Br J Clin Pharmacol 2011;71:642-6. [Ref.ID 90597]

Waller DG. Allergy, pseudo-allergy and non-allergy. Br J Clin Pharmacol 2011;71:637-8. [Ref.ID 90595]

Anónimo. What are excipients doing in medicinal products?. Drug Ther Bull 2009;47:81-4. [Ref.ID 86136]

Austen F, Woodcock J, Sasisekharan R. Contaminated heparin. The authors reply. N Engl J Med 2008;359:1293. [Ref.ID 83990]

Kakkar AK, Bonnefoi M. Contaminated heparin. N Engl J Med 2008;359:1292. [Ref.ID 83989]

Greinacher A, Warkentin TE. Contaminated heparin. N Engl J Med 2008;359:1291-2. [Ref.ID 83988]

Lapi F, Cecchi E, Pedone C, Attanasio F, Banchelli G, Vannacci A, Di Pirro M, Moschini M, Berni V, Matucci R, Cini E, Scalia A, Tendi E, Mugelli A. Safety aspects of iodinated contrast media related to their psychochemical properties: a pharmacoepidemiology study in two Tuscany hospitals. Eur J Clin Pharmacol 2008;64:723-37. [Ref.ID 83517]

Schwartz LB. Heparin comes clean. N Engl J Med 2008;358:2505-9. [Ref.ID 83135]

Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67. [Ref.ID 83131]

Avorn J. Coagulation and adulteration - Building on science and policy lessons from 1905. N Engl J Med 2008;358:2429-31. [Ref.ID 83129]

Bertele V, Assisi A, Di Muzio V, Renzo D, Garattini S. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol 2007;63:879-89. [Ref.ID 80979]